EBS Stock Analysis: Buy, Sell, or Hold?
EBS - Emergent Biosolutions, Inc.
$11.83
0.12 (1.02%)
▲
5d:
-3.19%
30d:
-5.44%
90d:
-5.21%
BUY
HIGH Confidence
Last Updated: February 2, 2026
Earnings: Mar 02, 2026
26d
Get Alerted When EBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called EBS this week
83% bullish • 1 bearish
83% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EBS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: EBS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$22.70
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$14.10
16.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EBS is currently trading at $11.83, which is considered fair relative to its 30-day fair value range of $11.46 to $12.86. The stock's valuation (Forward PE: 2.9) is in line with its historical norms (2.9). Remarkably, the market is currently pricing in an annual earnings decline of 0.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EBS is in a strong uptrend. Immediate support is located at $11.11, while resistance sits at $12.58.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.50 (+15.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EBS is in a strong uptrend. Immediate support is located at $11.11, while resistance sits at $12.58.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.50 (+15.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$11.46 -
$12.86
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($13.50)
Fair Price Analysis
30-Day Fair Range
$11.46 -
$12.86
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$1.22
(10.3%)
Support & Resistance Levels
Support Level
$11.11
Resistance Level
$12.58
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
2.91
Wall Street Target
$13.50
(+15.3%)
Revenue Growth (YoY)
-21.3%
Earnings Growth (YoY)
-55.8%
Profit Margin
9.6%
Valuation Discount vs History
-0.2% cheaper
PE vs Historical
2.9 vs 2.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.2%
(market-implied from PE analysis)
1-Year Target
$11.69
(0%)
2-Year Target
$11.66
(0%)
3-Year Target
$11.64
(-1%)
3-Yr Target (if PE normalizes)
(PE: 3→3)
PE COMPRESSION
$11.59
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 96.1%)
$302.56
(+2484%)
Base:
(SPY PE: 2.9, Growth: 96.1%)
$39.52
(+238%)
Bear:
(PE: 2.5, Growth: 96.1%)
$33.59
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (9x PE), but valuation improves significantly next year (3x PE) as earnings recover.
Trailing PE: 9.00 | Current EPS (TTM): $1.26
Bull Case
$24.95
(+113%)
Analyst growth 100.0%, PE expands to 9.9
Base Case
$22.68
(+94%)
Market implied 100.0%, PE stable at 9.0
Bear Case
$7.71
(-34%)
Severe decline -20.0%, PE contracts to 7.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 03, 2026 11:46 AM ET
Data refreshes hourly during market hours. Next update: 12:46 PM
Data refreshes hourly during market hours. Next update: 12:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Coleen Glessner
SELL
30608 shares
2025-10-07
Kathryn C Zoon
SELL
7086 shares
2025-08-15
Donald W Degolyer
SELL
7844 shares
2025-08-12
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 60 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 54 HOLD |
Advanced EBS Option Strategies
Professional options setups generated by AI based on today's EBS price and gamma walls.
